Brodsky M A, Sato D A, Allen B J, Chesnie B M, Henry W L
Chest. 1986 Jun;89(6):790-4. doi: 10.1378/chest.89.6.790.
To determine the clinical characteristics of patients with life-threatening ventricular tachyarrhythmias with no identifiable heart disease, we analyzed six patients who presented with either cardiac arrest or syncope associated with documented ventricular tachycardia or fibrillation. Electrocardiographic and echocardiographic examination and cardiac catheterization results were normal in all patients. Electrocardiographic monitoring revealed ventricular tachycardia in all patients. Exercise testing did not provoke sustained ventricular tachycardia in any patient. Programmed extrastimulation did not induce ventricular tachycardia in any patient. Isoproterenol infusion facilitated provocation of sustained ventricular tachycardia in only one patient. All six patients were treated with solitary beta-blocker therapy. Following treatment, there was a significant reduction in the incidence of ventricular tachycardia, couplets and total ventricular ectopic beats. During a follow-up period ranging from 16 to 36 (mean 22) months, all patients remain alive without clinically significant recurrence. Therefore, patients with life-threatening ventricular tachyarrhythmias without identifiable heart disease may respond to solitary beta-blocker therapy.
为确定无明确心脏病的危及生命的室性快速性心律失常患者的临床特征,我们分析了6例出现心脏骤停或与记录到的室性心动过速或颤动相关的晕厥的患者。所有患者的心电图、超声心动图检查及心导管检查结果均正常。心电图监测显示所有患者均有室性心动过速。运动试验未在任何患者中诱发持续性室性心动过速。程控额外刺激未在任何患者中诱发出室性心动过速。仅1例患者在输注异丙肾上腺素后诱发出持续性室性心动过速。所有6例患者均接受单一β受体阻滞剂治疗。治疗后,室性心动过速、成对室性早搏及室性异位搏动总数的发生率显著降低。在16至36(平均22)个月的随访期内,所有患者均存活,无具有临床意义的复发。因此,无明确心脏病的危及生命的室性快速性心律失常患者可能对单一β受体阻滞剂治疗有反应。